Gemcitabine and oxaliplatin in the treatment of patients with immunotherapy‐resistant advanced renal cell carcinomaCamillo Porta, Alberto Riccardi, Anna Natalizi et al.|Cancer|2004Cited by 23
Pro-neoangiogenic cytokines (VEGF and bFGF) and anemia in solid tumor patientsCamillo Porta, Alberto Riccardi, Ilaria Imarisio et al.|Oncology Reports|2005Cited by 6
869 Gemcitabine (GEM) and oxaliplatin (I-OHP) to treat immunotherapy-resistant advanced renal cell carcinoma (ARCC) patients (pts.): preliminary results of a single institution phase II studyCamillo Porta, Alberto Riccardi, Marco Danova et al.|European Journal of Cancer Supplements|2003Cited by 0